Literature DB >> 16434414

Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol.

Harald P Kühl1, Claudia S A Lipke, Gabriele A Krombach, Marcus Katoh, Thomas F Battenberg, Bernd Nowak, Nicole Heussen, Arno Buecker, Wolfgang M Schaefer.   

Abstract

AIMS: The aim of the study was to compare, in patients with chronic ischaemic cardiomyopathy, contrast-enhanced cardiovascular magnetic resonance (ce-CMR) imaging and a combined (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) and (99m)Tc-sestamibi single-photon emission computed tomography (SPECT) protocols for the prediction of functional recovery after revascularization, as assessed by cine CMR. METHODS AND
RESULTS: Twenty-nine patients with ischaemic cardiomyopathy (ejection fraction 32 +/- 10%) were investigated with ce-CMR and PET/SPECT. For the assessment of global and regional functions, cine CMR was performed at baseline and at 6 months follow-up. For ce-CMR, the segmental extent of hyperenhancement (SEH) was quantitated, and for PET/SPECT, different viability categories were defined according to a validated quantitative protocol. Functional improvement was related to the SEH by ce-CMR, as well as to the viability categories by PET/SPECT. Sensitivity and specificity for the prediction of functional recovery at follow-up was 97 and 68% for ce-CMR and 87 and 76% for PET/SPECT. The positive predictive value was identical for both techniques (73%). However, ce-CMR achieved a higher negative predictive value (93 vs. 77%, respectively), indicating that ce-CMR may be superior to PET/SPECT for the identification of segments unlikely to recover function after revascularization. Both methods had a similar yield in the prediction of global functional improvement.
CONCLUSION: ce-CMR is comparable with a PET/SPECT imaging protocol for the prediction of regional and global functional improvement after revascularization. However, ce-CMR may be superior to nuclear imaging for the identification of segments that are unlikely to recover function at follow-up.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434414     DOI: 10.1093/eurheartj/ehi747

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  29 in total

1.  Prediction of long-term reverse left ventricular remodeling after revascularization or medical treatment in patients with ischemic cardiomyopathy: a comparative study between SPECT and MRI.

Authors:  Tomas Skala; Martin Hutyra; Jan Vaclavik; Milan Kaminek; David Horak; Josef Novotny; Jana Zapletalova; Jan Lukl; Dan Marek; Milos Taborsky
Journal:  Int J Cardiovasc Imaging       Date:  2010-08-20       Impact factor: 2.357

Review 2.  PET and MRI in cardiac imaging: from validation studies to integrated applications.

Authors:  Stephan G Nekolla; Axel Martinez-Moeller; Antti Saraste
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-03       Impact factor: 9.236

3.  Mid-term results of coronary bypass graft surgery in patients with ischaemic left ventricular systolic dysfunction and no detected myocardial viability.

Authors:  Jun Liu; Zixiong Liu; Anqing Chen; Zhe Wang; Mi Zhou; Junfeng Cai; Qiang Zhao
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-02-23

4.  Improved diagnosis and prognosis using Decisions Informed by Combining Entities (DICE): results from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE).

Authors:  Mark Doyle; Gerald M Pohost; C Noel Bairey Merz; Leslee J Shaw; George Sopko; William J Rogers; Barry L Sharaf; Carl J Pepine; Diane A Vido-Thompson; Geetha Rayarao; Lindsey Tauxe; Sheryl F Kelsey; Douglas Mc Nair; Robert W Biederman
Journal:  Cardiovasc Diagn Ther       Date:  2013-12

5.  Viability assessment with MRI is superior to FDG-PET for viability: Pro.

Authors:  Jamshid Maddahi
Journal:  J Nucl Cardiol       Date:  2010-04       Impact factor: 5.952

Review 6.  CSI position statement on management of heart failure in India.

Authors:  Santanu Guha; S Harikrishnan; Saumitra Ray; Rishi Sethi; S Ramakrishnan; Suvro Banerjee; V K Bahl; K C Goswami; Amal Kumar Banerjee; S Shanmugasundaram; P G Kerkar; Sandeep Seth; Rakesh Yadav; Aditya Kapoor; Ajaykumar U Mahajan; P P Mohanan; Sundeep Mishra; P K Deb; C Narasimhan; A K Pancholia; Ajay Sinha; Akshyaya Pradhan; R Alagesan; Ambuj Roy; Amit Vora; Anita Saxena; Arup Dasbiswas; B C Srinivas; B P Chattopadhyay; B P Singh; J Balachandar; K R Balakrishnan; Brian Pinto; C N Manjunath; Charan P Lanjewar; Dharmendra Jain; Dipak Sarma; G Justin Paul; Geevar A Zachariah; H K Chopra; I B Vijayalakshmi; J A Tharakan; J J Dalal; J P S Sawhney; Jayanta Saha; Johann Christopher; K K Talwar; K Sarat Chandra; K Venugopal; Kajal Ganguly; M S Hiremath; Milind Hot; Mrinal Kanti Das; Neil Bardolui; Niteen V Deshpande; O P Yadava; Prashant Bhardwaj; Pravesh Vishwakarma; Rajeeve Kumar Rajput; Rakesh Gupta; S Somasundaram; S N Routray; S S Iyengar; G Sanjay; Satyendra Tewari; Sengottuvelu G; Soumitra Kumar; Soura Mookerjee; Tiny Nair; Trinath Mishra; U C Samal; U Kaul; V K Chopra; V S Narain; Vimal Raj; Yash Lokhandwala
Journal:  Indian Heart J       Date:  2018-06-08

7.  Non-invasive cardiac imaging technologies for the assessment of myocardial viability: a summary of evidence-based analyses.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2010-07-01

Review 8.  Practical applications of cardiovascular magnetic resonance.

Authors:  F Alpendurada; J Wong; D J Pennell
Journal:  Heart Asia       Date:  2009-01-01

9.  Agreement and disagreement between contrast-enhanced magnetic resonance imaging and nuclear imaging for assessment of myocardial viability.

Authors:  Stijntje D Roes; Theodorus A M Kaandorp; Nina Ajmone Marsan; Jos J M Westenberg; Petra Dibbets-Schneider; Marcel P Stokkel; Hildo J Lamb; Ernst E van der Wall; Albert de Roos; Jeroen J Bax
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-03       Impact factor: 9.236

Review 10.  Noninvasive assessment myocardial viability: current status and future directions.

Authors:  Kevin C Allman
Journal:  J Nucl Cardiol       Date:  2013-06-15       Impact factor: 5.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.